Management of Rheumatoid Arthritis: An Overview

Rheumatoid arthritis (RA) is a multifactorial autoimmune disease of unknown etiology, primarily affecting the joints, then extra-articular manifestations can occur. Due to its complexity, which is based on an incompletely elucidated pathophysiological mechanism, good RA management requires a multidi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Andrei-Flavius Radu, Simona Gabriela Bungau
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	rheumatoid arthritis anti-citrullinated protein antibodies rheumatoid factor extra-articular manifestations DMARDs Janus kinase inhibitors Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/45fc4e972b9a46aaa9b74c8fc12fc72b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:45fc4e972b9a46aaa9b74c8fc12fc72b
record_format	dspace
spelling	oai:doaj.org-article:45fc4e972b9a46aaa9b74c8fc12fc72b2021-11-25T17:08:08ZManagement of Rheumatoid Arthritis: An Overview10.3390/cells101128572073-4409https://doaj.org/article/45fc4e972b9a46aaa9b74c8fc12fc72b2021-10-01T00:00:00Zhttps://www.mdpi.com/2073-4409/10/11/2857https://doaj.org/toc/2073-4409Rheumatoid arthritis (RA) is a multifactorial autoimmune disease of unknown etiology, primarily affecting the joints, then extra-articular manifestations can occur. Due to its complexity, which is based on an incompletely elucidated pathophysiological mechanism, good RA management requires a multidisciplinary approach. The clinical status of RA patients has improved in recent years due to medical advances in diagnosis and treatment, that have made it possible to reduce disease activity and prevent systemic complications. The most promising results were obtained by developing disease-modifying anti-rheumatic drugs (DMARDs), the class to which conventional synthetic, biologic, and targeted synthetic drugs belong. Furthermore, ongoing drug development has led to obtaining molecules with improved efficacy and safety profiles, but further research is needed until RA turns into a curable pathology. In the present work, we offer a comprehensive perspective on the management of RA, by centralizing the existing data provided by significant literature, emphasizing the importance of an early and accurate diagnosis associated with optimal personalized treatment in order to achieve better outcomes for RA patients. In addition, this study suggests future research perspectives in the treatment of RA that could lead to higher efficacy and safety profiles and lower financial costs.Andrei-Flavius RaduSimona Gabriela BungauMDPI AGarticlerheumatoid arthritisanti-citrullinated protein antibodiesrheumatoid factorextra-articular manifestationsDMARDsJanus kinase inhibitorsBiology (General)QH301-705.5ENCells, Vol 10, Iss 2857, p 2857 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	rheumatoid arthritis anti-citrullinated protein antibodies rheumatoid factor extra-articular manifestations DMARDs Janus kinase inhibitors Biology (General) QH301-705.5
spellingShingle	rheumatoid arthritis anti-citrullinated protein antibodies rheumatoid factor extra-articular manifestations DMARDs Janus kinase inhibitors Biology (General) QH301-705.5 Andrei-Flavius Radu Simona Gabriela Bungau Management of Rheumatoid Arthritis: An Overview
description	Rheumatoid arthritis (RA) is a multifactorial autoimmune disease of unknown etiology, primarily affecting the joints, then extra-articular manifestations can occur. Due to its complexity, which is based on an incompletely elucidated pathophysiological mechanism, good RA management requires a multidisciplinary approach. The clinical status of RA patients has improved in recent years due to medical advances in diagnosis and treatment, that have made it possible to reduce disease activity and prevent systemic complications. The most promising results were obtained by developing disease-modifying anti-rheumatic drugs (DMARDs), the class to which conventional synthetic, biologic, and targeted synthetic drugs belong. Furthermore, ongoing drug development has led to obtaining molecules with improved efficacy and safety profiles, but further research is needed until RA turns into a curable pathology. In the present work, we offer a comprehensive perspective on the management of RA, by centralizing the existing data provided by significant literature, emphasizing the importance of an early and accurate diagnosis associated with optimal personalized treatment in order to achieve better outcomes for RA patients. In addition, this study suggests future research perspectives in the treatment of RA that could lead to higher efficacy and safety profiles and lower financial costs.
format	article
author	Andrei-Flavius Radu Simona Gabriela Bungau
author_facet	Andrei-Flavius Radu Simona Gabriela Bungau
author_sort	Andrei-Flavius Radu
title	Management of Rheumatoid Arthritis: An Overview
title_short	Management of Rheumatoid Arthritis: An Overview
title_full	Management of Rheumatoid Arthritis: An Overview
title_fullStr	Management of Rheumatoid Arthritis: An Overview
title_full_unstemmed	Management of Rheumatoid Arthritis: An Overview
title_sort	management of rheumatoid arthritis: an overview
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/45fc4e972b9a46aaa9b74c8fc12fc72b
work_keys_str_mv	AT andreiflaviusradu managementofrheumatoidarthritisanoverview AT simonagabrielabungau managementofrheumatoidarthritisanoverview
_version_	1718412709861523456

Management of Rheumatoid Arthritis: An Overview

Ejemplares similares